A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Dajun Yang et al.|Journal of Clinical Oncology|2019Cited by 27
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.Anthony W. Tolcher, Yifan Zhai, James A. Reeves et al.|Journal of Clinical Oncology|2021Cited by 23
First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.Nehal J. Lakhani, Yifan Zhai, Drew Rasco et al.|Journal of Clinical Oncology|2020Cited by 20
A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Yufeng Li et al.|Journal of Clinical Oncology|2019Cited by 11
Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2020Cited by 6